Elusys Therapeutics has published data from five clinical trials of ANTHIM, which was used to support the marketing approval by the U.S. Food and Drug Administration.  Read More »

Apintyx Inc. will develop its lead compound, NYX-2925, to treat neuropathic pain linked to diabetic peripheral neuropathy. Read More »

Avara Pharmaceutical Services Inc. recently celebrated the one-year anniversary of its purchase of the Arecibo site in Puerto Rico from Merck. Read More »

CVS Health reported this week that it has increased access to naloxone, the opioid overdose-reversal medication, to include five new states — Alabama, Alaska, Illinois, Missouri and West Virginia. Read More »

AbbVie recently announced that the small molecule active pharmaceutical ingredient (API) facility constructed at its Singapore manufacturing site is now open. Read More »

Allergan Inc. recently announced the acquisition of Akarna Therapeutics for an upfront payment of $50 million.   Read More »

Abbott announced this week that its FreeStyle Libre Pro system, a groundbreaking continuous glucose monitoring (CGM) system designed for patients with diabetes, has been approved by the U.S. Food and Drug Administration (FDA).re Read More »

Perrigo Co. this week announced that it has agreed to an exclusive licensing agreement with Highland Pharmaceuticals LLC for its methamphetamine (meth) blocking technology called Tarex. Read More »

Jazz Pharmaceuticals plc recently reported that enrollment for its two Phase 3 clinical trials for JZP-110 has been finalized. Read More »

Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). Read More »

Tarix Orphan LLC recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to TXA127, the company’s prospective treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. Read More »

Armetheon Inc., a specialty pharmaceutical company that focuses on the development of novel small molecule drugs for the treatment of cardiovascular diseases, recently released the results of its Phase 1 clinical trial assessing how the pharmacokinetics (PK) of tecarfarin and of warfarin is affected by severe chronic kidney disease (CKD). Read More »

Allergen plc recently announced that NAMZARIC is now available through prescription in pharmacies across the United States. Read More »

Mylan N.V. and Biocon Ltd. recently announced that Mylan’s Marketing Authorization Application (MAA) for Trastuzumab has been accepted by the European Medicines Agency (EMA) for review.  Read More »

PharmaMar recently submitted a Marketing Authorization Application (MAA) for Aplidin to the European Medicines Agency (EMA). Read More »

Mark Merritt, president and CEO of the Pharmaceutical Care Management Association (PCMA), recently testified before the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law. Read More »

Meridian Bioscience Inc. has officially launched its Analyte Specific Reagent (ASR) line of products. Read More »

Medivir AB announced last week the release of new data from its Phase IIa MIV-711-201 trial. Read More »

Faraday Pharmaceuticals recently announced the start of its FDY-5301 Phase 1 clinical study, which is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of FDY-5301, the company’s lead compound. Read More »

Portola Pharmaceuticals Inc. recently announced it has submitted a Marketing Authorization Application (MAA) for IndexXa to the European Medicines Agency, noting that the validation period has been completed and it has been accepted for review. Read More »